Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
The DIAN‐TU acknowledges the many individuals who have contributed to the DIAN‐TU Trials including funding partners, leadership team, core leaders, project arm leaders, study sites and institutional study partners listed in the following pages. All manuscripts should include one of the following statements of acknowledgement of the DIAN‐TU Team located at DIAN.wustl.edu.
General DIAN‐TU and/or DIAN‐TU Trial Platform (not drug specific or all drugs): The DIAN‐TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN‐TU Pharma Consortium (https://dian.wustl.edu/our‐research/the‐pharma‐consortium/). The DIAN‐TU‐001 Trial has received support from the Alzheimer’s Association, Eli Lilly and Company, Roche, Janssen Pharmaceuticals, NIH U01AG042791, NIH U01AG042791‐S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, NIH R01/R56 AG053267, Avid Radiopharmaceuticals, Cogstate, Bracket, GHR Foundation, and an anonymous organization. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN‐TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp‐content/uploads/2019/04/DIAN‐TU‐Publications_Acknowledgement_V25.pdf) for their contributions to this study.
DIAN‐TU Trial Platform ‐ Sola/Gant specific: The DIAN‐TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN‐TU Pharma Consortium (https://dian.wustl.edu/our‐research/the‐pharma‐consortium/). This research for the DIAN‐TU‐001 Trial has received support from the Alzheimer’s Association, Eli Lilly and Company, Roche, NIH U01AG042791, NIH U01AG042791‐S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, Avid Radiopharmaceuticals, Cogstate, Bracket, GHR Foundation, and an anonymous organization. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN‐TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp‐content/uploads/2019/04/DIAN‐TU‐Publications_Acknowledgement_V25.pdf) for their contributions to this study.
DIAN‐TU Trial Platform – Atabecestat specific: The DIAN‐TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN‐TU Pharma Consortium (https://dian.wustl.edu/our‐research/the‐pharma‐consortium/). This research for the DIAN‐TU‐001 Trial has received support from the Alzheimer’s Association, Janssen Pharmaceuticals, NIH R01/R56 AG053267, GHR Foundation, and an anonymous organization. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN‐TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp‐content/uploads/2019/04/DIAN‐TU‐Publications_Acknowledgement_V25.pdf) for their contributions to this study.
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Publication Authorship: The overarching considerations for DIAN‐TU publications are collaboration and inclusiveness. When studies use DIAN‐TU Trial data and/or biospecimens processed by the DIAN‐TU Coordinating Center Cores, an invitation to collaborate (meriting authorship) on the manuscript should be issued to respective DIAN‐TU Study Team Members as defined below:
DIAN‐TU Study Team Members (see complete list of individuals on pages 3‐20)
Invite to co‐author:
Leadership Team Pharma Partners Core Leaders (Core leaders may include staff member, fellow, co‐investigator) Site Principal Investigators
Acknowledge: DIAN‐TU Staff Pharma Teams Commercial Vendors and Collaborators DSMB Members Therapy Evaluation Committee Clinical Trials Committee Data Sharing and Communications Committee DIAN EXR Referring Clinicians and Researchers DIAN‐TU Advisers and Collaborators
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Funding Partners Through public/private support and partnership, the DIAN‐TU has launched trials to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer’s disease drug developments. DIAN‐TU Trial Pharma Partners: Lilly (Solanazemab), Roche (Gantenerumab) and Janssen (BACEi)
Alzheimer’s Association GHR Foundation National Institute on Aging of the National Institutes of Health; Accelerating Medicines
Partnership (AMP) ‐ U01 AG042791, R01 AG046179, R01/R56 AG053267, R13 AG055232 DIAN‐TU Pharma Consortium: Biogen Idec, Eisai, Janssen, Lilly, Roche/Genentech, United
NeuroScience (Former Members: Abbvie, Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis Pharm AG, Pfizer, Sanofi‐Aventis)
CogState Bracket Avid Radiopharmaceuticals Anonymous Foundation
Leadership Team
Washington University School of Medicine, Department of Neurology Randall Bateman, MD Eric McDade, DO Director and Principal Investigator DIAN‐TU Associate Director, DIAN‐TU
David Clifford, MD Medical Director
Project Arm Leaders Steve Salloway, MD, Gantenerumab Martin Farlow, MD, Solanazemab Butler Hospital Indiana University
Lon Schneider, MD, BACE Butler Hospital Pharma Partners Eli Lilly Hoffman La‐Roche Janssen John Sims Greg Klein Gary Romano Cheryl Brown Smilijana Ristic Hong Sun Eric Siemers (retired) Monika Baudler Luc Tritsman (retired)
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
DIAN‐TU Core Leaders
Randall Bateman, MD Administrative Core Leader Washington University School of Medicine Anne Fagan, PhD Biomarker Core Leader Washington University School of Medicine Chengjie Xiong, PhD Biostatistics Core Leader Washington University School of Medicine Guoqiao Wang, PhD Biostatistics Co‐Core Leader Washington University School of Medicine Jason Hassenstab, PhD Cognition Core Leader Washington University School of Medicine Alison Goate, DPhil Genetics Core Leader Mt. Sinai School of Medicine Carlos Cruchaga, PhD Genetics Core Leader Washington University School of Medicine Tammie Benzinger, MD Imaging Core Leader Washington University School of Medicine Rick Perrin, MD Neuropathology Core Leader Washington University School of Medicine Cliff Jack, MD MRI, Mayo Clinic Robert Koeppe, MD PET Imaging, University of Michigan
Nigel Cairns, MD (retired) Neuropathology Core Leader Washington University School of Medicine
Peter Snyder, PhD (Former Cognition Core Leader) Brown University
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
DIAN‐TU Staff
Administration Garland Edmonds, Accounting/Purchasing Assistant
Amanda Fulbright, Grant Specialist
Jacki Mallmann, Senior Grant Specialist
Karen McCann, Financial Accounting Assistant
Julie Murphy, Accounting/Purchasing Assistant Anna Santacruz, Administrative Director
Jeanette Schillizzi – Research Administrator
Shannon Sweeney, Finance Analyst
Linda Watkins‐Imhof, Accounting/Purchasing Assistant
Biomarker Kelley Coalier, Lead Scientist
Matt Amos, Lead Technician
Fatima Amtashar, QC Technician
Sushila Sathyan, Archivist
Clinical Operations
Susan Mills – Director of Clinical Operations
Nicole Kelley ‐ Associate Director of Clinical Operations
Stephanie Belyew ‐ Clinical Research Development Coordinator, Site, Vendor and GCP Management
Angela Fuqua ‐ Clinical Research Development Coordinator, Clinical Scale, Drug Supply and Vendor Management
Annette Stiebel ‐ Clinical Research Development Coordinator
Caryll Bentley ‐ Contract Project Manager
JaNeen Wisner ‐ Contract Project Coordinator
Tayona Mayhew ‐ Data Management Specialist
Zenobia Bridgewater ‐ Clinical Research Coordinator
Erin Cattoor ‐ Research Nurse Coordinator II
Molly Fitzgerald – Clinical Research Study Assistant I
Erica Fowler ‐ Clinical Research Coordinator I
Kurtis Hanks ‐ Clinical Research Coordinator I
Dottie Heller ‐ Research Nurse Coordinator II
Latoya Jones ‐ Clinical Research Coordinator II
Paulette MacDougall ‐ Research Nurse Coordinator II
Michelle Jorke ‐ Clinical Research Coordinator II
Eugene Rubin ‐ QC
Jessi Smith ‐ Senior Clinical Research Coordinator
Marisol Tahan ‐ Clinical Research Coordinator
Mary Wolfsberger ‐ Clinical Research Coordinator
Biostatistics Yan Li ‐ Co‐Investigator
Xu Xiong ‐ Database Manager
Cognition Andy Aschenbrenner – Research Instructor
Jennifer Smith ‐ Professional Rater III
DIAN Expanded Registry (DIAN EXR) Eric McDade ‐ Director
Randall Bateman – Associate Director
Jorge Llibre‐Guerra – Post‐Doctoral Associate
Ellen Ziegemeier ‐ Senior Clinical Research Coordinator
Jennifer Petranek ‐ Clinical Coordinator I
Sarah Adams ‐ Clinical Research Coordinator II
Susan Brandon ‐ Clinical Research Coordinator II
DIAN‐TU Post‐Doctoral Associate(s) Jorge Llibre‐Guerra – Post‐Doctoral Associate
Imaging Theresa Butler ‐ Research Lab Manager
Lisa Cash ‐ Senior Clinical Research Coordinator
Jon Christensen ‐ Staff Scientist
Aylin Dincer ‐ Research Assistant
Tony Durbin ‐ Senior Clinical Research Coordinator
Shaney Flores ‐ Research Assistant
Karl Friedrichsen ‐ Research Assistant
Brian Gordon ‐ Co‐Investigator
Russ Hornbeck ‐ Project Manager
Nelly Joseph‐Mathurin ‐ Post‐doc
Sarah Keefe ‐ Research Assistant
Lakisha Lloyd ‐ Research Coordinator
Laura Marple ‐ Research Technician II
Austin McCullough ‐ Graduate Research Assistant
Jeanine Portell ‐ Senior Clinical Research Coordinator
Stephanie Schultz ‐ Pre‐Doctoral Trainee
Sally Schwarz ‐ Co‐Investigator
Yi Su ‐ Co‐Investigator
Andrei Vlassenko ‐ Co‐Investigator
Qing Wang ‐ Post‐doc
Jinbin Xu ‐ Co‐Investigator
Neuropathology Erin Franklin ‐ Research Coordinator
Erin Cattoor ‐ Research Nurse Coordinator II
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Eli Lilly Team John Sims, GBD Leader and Senior Medical Director Cheryl Brown, COO Roy Yaari, Senior Medical Advisor Karen Chilcotte Holdridge, CRS Isabella Velona, Clinical Trial Project Manager Scott Andersen, Biostatistician Michele Mancini, GPS Brian Willis, PK/PD Project Leader Sonia Nijampatnam, Pharmaceutical Project Management Kathryn Broderick, Global Regulatory Affairs Julie Bush, Product Delivery Shamrock Garrett, Sr. CTMA Traci Peddie, Data Sciences & Solutions Natalie Vantwoud, Data Management Barbara Lightfoot‐Owens, Medical Writer John Brad‐Holmes, Central Lab
Former
Phyllis Ferrell Barkman Russ Barton Lauren Brunke Robert Dean Deanilee Deckard Ann Catherine Downing Ganapathy Goppalrathnam David Henley Janice Hitchcock Tracie Peddie Melissa Pugh Tami Jo Rayle Shiloh Scott James Senetar Gopalan Sethuraman Eric Siemers Brian Steuenwald Connie Tong Jim Vandergriff
Avid Michael Devous Erica Elephant Laura Harper Marybeth Howlett Mark Mintun Michael Pontecorvo
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Hoffman‐LaRoche Team Monika Baudler, LifeCycle Leader
Rachelle Doody, Global Head of Neurodegneration
Paul Delmar, Principal Statistical Scientist
Carsten Hofmann, Clinical Pharmacologist
Michaela Jahn, Global Biometrics Team Leader
Geoff Kerchner, Global Development Leader
Gregory Klein, Biomarker Experimental Medicine Leader
Smiljana Ristic, Associate Group Medical Director
Alison Searle, Operations Program Leader
Marco Sonderegger, Technical Development Leader
Roz Sutton, EU Regulatory Partner
Janette Turner, US Regulatory Partner
Jaku Wojtowicz, Safety Science Director
Susan Yule, Global Regulatory Leader
Former Elizabeth Ashford, Operations Program Leader Bogdon Balas, Safety Science Leader Estelle Vester‐Blokland, LifeCycle Leader Stephanie Capo‐Chichi, EU Regulatory Partner
David Agnew, Global Study Manager Ernest Dorflinger, Translational Medicine Leader Efe Egharevba, Global Study Manager Christelle Laroche, Technical Development Leader
Isabelle Bauer Dauphin, Technical Development Leader Rob Lasser, Global Development Leader Ferenc Martenyi, Global Development Leader Glenn Morrison, Global Development Leader Tania Nikolcheva, Biomarker Experimental Medicine Leader Michael Rabbia, Statistical Scientist Juha Savola, Project Leader Janice Smith, Clinical Science Leader Dietmar Volz, Statistical Scientist
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Janssen Team Caitlin Beatty
Jennifer Bogert
Miranda Damen
Carol Davies
Marisa Ehinger
Suzanne Foy
Monique Franc
Betty Guinter
Katrin Haeverans
Megan Katz
Hartmuth Kolb
Cathy Marseca
Reena Mistry
Sophie Morin
Gary Romano
Maria Schpatschynskyj
Hong Sun
Monika Sulidis
Luc Tritsman
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
The following should be acknowledged in DIAN‐TU Publications Commercial Vendors and Collaborators DSMB Members Therapy Evaluation Committee Clinical Trials Committee Data Sharing and Communications Committee DIAN EXR Referring Clinicians and Researchers DIAN‐TU Advisers and Collaborators
DIAN‐TU Commercial Vendors and Collaborators IQVIA Lynne Hughes Miriana Vankov Denise Dormody Ryan Thompson Frederique Alary Carla Hancock Kim Hughes Eva Irmy David Margolin, MD Olja Tanjga, MD Deitra Wade
Berry Consultants Scott Berry Melanie Quintana Barbara Wendelberger
CogState Granzer Regulatory Consulting Cardinal Health Regulatory Sciences Signat
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
DIAN‐TU DSMB Members
The DSMB is an expert advisory group who functions as a review committee independent from the Sponsor. DSMB members meet without the Sponsor or study team members to review and discuss provided data. The DSMB scope is to review study data to ensure the safety of subjects enrolled in DIAN‐TU‐001.
Gary Cutter, DSMB Chairperson
Steve Greenberg
Scott Kim
David Knopman
Willis Maddrey (Retired)
Kristine Yaffe
Karl Kieburtz (Retired DSMB Chairperson)
Allan Levey (Retired)
DIAN‐TU Data Sharing and Communications Committee
Andy Aschenbrenner, PhD, Committee Chair Anna Santacruz, Administrative Director
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
DIAN‐TU Therapy Evaluation Committee The DIAN‐TU established a Therapy Evaluation Committee comprised of worldwide experts in AD research and clinical studies from multiple institutions to vet and evaluate compounds nominated for participation in the DIAN‐TU trial. Areas of expertise include clinical trials in AD and other diseases, autosomal dominant and sporadic AD, immunotherapy, neurodegenerative disorders, cell and molecular biology of AD, preclinical AD studies, proteomics (AD related proteins), AD neuropathology, cognitive and clinical testing, cerebral amyloid angiopathy, neuroimaging, translational AD trials, and tau biology. Randall Bateman, MD, Chair, Washington University Eric McDade, DO, Co‐Chair, Washington University Paul Aisen, MD, Alzheimer's Therapeutic Research Institute (clinical trials)
Jasmeer Chhatwal, MD, PhD, MMSc, Massachusetts General Hospital, Harvard Medical School (imaging)
David Clifford, MD, Washington University School of Medicine (Medical Director, DIAN‐TU Trials)
David Cribbs, MD, UC Irvine (immunotherapy)
Nick Fox, MD, FRCP, FMedSci, Dementia Research Centre (genetics)
Serge Gauthier, Serge Gauthier, CM, MD, FRCPC, Director, AD & Related Disorders Unit
McGill Centre for Studies in Aging (clinical trials)
David Holtzman, MD, Washington University School of Medicine (neurodegeneration, animal models)
Matthias Jucker, PhD, Hertie Institute for Clinical Brain Research (translational AD)
Jeff Kelly, MD, Scripps (proteomics)
Virginia Lee, PhD, University of Pennsylvania, Perelman School of Medicine (tau biology)
Simon Mead, FRCP, PhD, Institute of Prion Diseases (genetics)
Cath Mummery, PhD, FRCP, Dementia Research Centre (genetics)
Erik Musiek, MD, PhD, Washington University School of Medicine (translational AD)
Erik Roberson, MD, PhD, University of Alabama (tau proteins)
Mathias Staufenbiel, PhD, Hertie Institute for Clinical Brain Research, Tubingen (pre‐clinical and clinical AD studies)
Robert Vassar, PhD, Northwestern (cell and molecular biology)
Former TEC Members
Bart DeStrooper, PhD, VIB, K.U. Leuven, Germany
William Klunk, MD, PhD, University of Pittsburgh, Pennsylvania
Cynthia Lemere, MD, Brigham and Women’s Hospital, Boston, Massachusetts
John C. Morris, MD, Washington University School of Medicine, St. Louis, Missouri
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Clinical Trials Committee (CTC) Members
Randall Bateman, Washington University in St. Louis School of Medicine
John Morris, Washington University in St. Louis School of Medicine
Chengjie Xiong, Washington University in St. Louis School of Medicine
Denise Heinrichs, DIAN Family Representative
John Ringman University of California, Los Angeles
Laurie Ryan, Division of Science, National Institute on Aging
Neil Buckholtz, National Institute on Aging
Reisa Sperling, Director, Center for Alzheimer Research and Treatment
Stephen Salloway, Butler Hospital
Paul Aisen, University of California, San Diego
Anna Santacruz, Washington University in St. Louis School of Medicine
Gabrielle Strobel, Alzheimer Research Forum
Bill Klunk, University of Pittsburgh
William Thies, Alzheimer's Association
CTC Steering Committee Members
Anne Fagan, Washington University in St. Louis School of Medicine
Mark Mintun, Washington University in St. Louis School of Medicine
Natalie Ryan, University College London
Virginia Buckles, Washington University in St. Louis School of Medicine
David Hawver, FDA
Martin Farlow, Indiana University
Maritza Ciliberto, DIAN Family Representative
Ralph Martins, Edith Cowan University
Jennifer Williamson, Columbia University
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites
Argentina Insituto de Investigaciones Neurologicas Fleni https://www.fleni.org.ar/especialidades/neurologia/neurologia‐cognitiva‐neuropsicologia‐y‐neuropsiquiatria/ Ricardo F. Allegri Principal Investigator
Patricio Chrem Mendez Co‐Investigator
Lucia Crivelli Neuropsychologist
Ezequiel Surace Biologist
Gustavo Sevlever Neuropathologist
Silvia Vazquez Imaging Principal Investigator
Luciana Armanini Study Coordinator
Australia Neuroscience Research –Sydney (SG, AV) William Brooks Principal Investigator
Michael J Fulham Imaging Principal Investigator
Jacob Bechara Study Coordinator
David Foxe CDR assessments
Australian Alzheimer’s Research Foundation – Perth (SG) Roger Clarnette Principal Investigator
Nick Reynders Imaging Principal Investigator
Paula Mather Study Coordinator
University of Melbourne – Melbourne (SG, AV) Colin Masters Principal Investigator
Christopher Rowe Imaging Principal Investigator
Bev Clinch Study Coordinator
David Baxendale Back up Coordinator
Brazil University of São Paulo Ricardo Nitrini Principal Investigator
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued)
Canada Douglas Hospital Research Centre (SG, AV) Serge Gauthier Principal Investigator
Pedro Rosa‐Neto Imaging Co‐Investigator
Carley Mayhew Study Coordinator
Laura Robb Back up Coordinator
Vancouver Coastal Health Authority (SG, AV) Robin Hsiung Principal Investigator
Dan Worsley Imaging Principal Investigator
Michele Assaly Study Coordinator
Eloise Nicklin Back up Coordinator
Sunnybrook Health Science Centre (SG, AV) Mario Masellis Principal Investigator Katie Sharp Study Coordinator
Stephanie Hetherington Back up Coordinator
Universite Laval Robert Laforce Principal Investigator
Colombia Grupo de Neurociencias Sede de la Universidad de Antioquia Francisco Lopera Principal Investigator
Yakeel Quiroz Sub‐Investigator
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued) France CHU de Rouen (SG, AV) www.alzheimer‐genetique.fr David Wallon, MD, PhD Principal Investigator
Didier Hannequin, MD, PhD Sub‐investigator
Alexandre Morin, MD Sub‐Investigator
Aline Zarea, MD Sub‐investigator
Emmanuel Gerardin, MD, PhD MRI Neuroimaging Investigator
Pierre Bohn, PharmaD Imaging principal Investigator
Mathieu Chastan, MD Imaging Sub‐Investigator
Pierre Vera, MD, PhD Imaging Sub‐Investigator
Marion Colnot, Pharma D Hospital Pharmacist
Nathalie Donnadieu, PharmaD Hospital Pharmacist
Muriel Quillard‐Muraine, MD, PhD Biologist
Celine Bergot Study Coordinator Severine Jourdain Back‐up Study Coordinator Hopital Larrey – Angers (SG) Valérie Chauviré, MD Sub‐investigator Frédérique Etcharry‐Bouyx, MD Sub‐investigator
Groupe Hospitalier Pitie (SG, AV) Bruno Dubois Principal Investigator
Marie‐Odile Habert Imaging Principal Investigator
Nadjia Younsi Back up Coordinator
Hopital Neurologique Pierre Wertheimer– Lyon (SG) Maite Formaglio Principal Investigator
Didier Lebars Imaging Principal Investigator
Najat El Kfif Study Coordinator
Aurélie Jullien Back up Coordinator
CHU de Toulouse (SG, AV) Jereme Pariente Principal Investigator
Pierre Payoux Imaging Principal Investigator
Claire Thalamas CID
Amel Driff CRA
Elsa Pomies Neuropsychologist Pascale Gauteul Study Coordinator
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued)
France (continued) Centre Hospitalier Unversitaire - Lille (SG, AV) Florence Pasquier Principal Investigator Adeline Rollin‐Sillaire Co‐Investigator
Franck Semah Imaging Principal Investigator Laetitia Breuilh Study Coordinator Manon Laforce Back up Coordinator Michael Bottlaender, MD, PhD Imaging Principal Investigator
Orsay Imaging Michael Bottlaender, MD, PhD Imaging Principal Investigator
Germany German Center for Neurodegenerative Diseases (DZNE), Universitaetsklinikum Tuebingen Christoph Laske Principal Investigator
Ludwig-Maximilians-Universität Johannes Levin Principal Investigator
Adrian Danek Principal Investigator (retired)
Jonathan Vöglein Co‐Investigator
Igor Yakushev Imaging Principal Investigator
Siri Houeland di Bari Study Coordinator
Ireland St. Vincent’s University Hospital Justin Kinsella Principal Investigator
Gillian O'Boyle Study Coordinator
Italy
Azienda Ospedaliera Universitaria Careggi Sandro Sorbi Principal Investigator
IRCCS Centro San Giovanni di Dio Fatebenefratelli Giovanni Frisoni Principal Investigator
Sara Gipponi Study Coordinator
Michela Rampini Study Coordinator
Anna Mega Genetic Counseling
Emilio Di Maria, MD Geneticist
Samantha Galluzzi, MD Geriatrician
Amalia Cecilia Bruni Neurologist
Nicoletta Smirne Statistician
Valentina Laganà Psychologist
Fabrizio Tagliavini Neurologist
Cristina Muscio Psychologist
Alessandro Padovani Neurologist
Barbara Borroni Neurologist
Elio Scarpini Neurologist
Gabriella Salvini Porro President, Federazione Alzheimer Italia
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued) Mexico Instituto Nacional de Neurologica y Neurocirugla Ana Luisa Sosa Principal Investigator
Longoria Mariana Co‐Investigator
Netherlands Amsterdam University Medical Centers Phillip Scheltens Principal Investigator
Spain Hospital Clinic I Provincial de Barcelona (SG, B, AV) Raquel Sanchez‐Valle Principal Investigator
Mircea Balasa Co‐Investigator
Albert Lladó Co‐Investigator
Beatriz Bosch Study Coordinator
Nuria Bargalló Imaging Co‐Investigator
Ignacio Banzo Imaging Co‐Investigator
Andres Perisinotti Imaging Principal Investigator
United Kingdom
University College London Hospital (SG)
Catherine Mummery Principal Investigator
Irfan Kayani Imaging Principal Investigator
Jane Douglas Study Coordinator
Miguel Grilo Co‐Investigator
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued)
United States Washington University, St. Louis, Missouri (SG, B, AV, MK)
Barbara J. Snider, MD Principal Investigator
Tammie Benzinger, MD Imaging Principal Investigator
Wendy Sigurdson, RN Study Coordinator
Tamara Donahue, RN Study Coordinator
Peggy Kelly, RN Study Coordinator
Emory University, Atlanta, Georgia (SG, B, AV, MK) James Lah Principal Investigator
Carolyn Meltzer Imaging Principal Investigator
Gail Schwartz Study Coordinator
Phyllis Vaughn Study Coordinator
Lydia Piendel Study Coordinator
University of Pittsburgh, Pennsylvania (SG, B, AV, MK) Sarah Berman Principal Investigator
James Mountz Imaging Principal Investigator
Lori Macedonia Study Coordinator
Snezana Ikonomovic Back up Coordinator
Sarah Goldberg, M.S. Neuropsychometrist
Elise Weamer, MPH Neuropsychometrist
James Ruskiewiecz, BS PET Research Manager
Steven Hegedus MR Research Assistant
Lee Tarr MR Research Technologist
Tom Potter MR Research Technologist
Gina Valetti MR Research Technologist
University of Alabama at Birmingham (SG, B, AV, MK)
Erik D. Roberson Principal Investigator
David S. Geldmacher Co‐Investigator
Marissa Natelson Love Co‐Investigator
Amber Watkins Study Coordinator
Loren Ashley Back up Coordinator
Indiana University (SG, B, AV, MK)
Jared R. Brosch, M.D. Principal Investigator
Brand Mathews, M.D. Former Principal Investigator
Arlene Kohn Study Coordinator
Nancy McClaskey, RN Study Coordinator
Jill Buck, RN Study Coordinator
James Fletcher Imaging Principal Investigator
Butler Hospital, Providence, Rhode Island (SG, B, AV, MK) Ghulam Surti Principal Investigator
Richard Noto Imaging Principal Investigator
Courtney Bodge Study Coordinator
William Menard Back up Coordinator
Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Study Sites (continued)
United States University of Puerto Rico (SG, B, AV, MK) Ivonne Z. Jimenez Velazquez Principal Investigator
Janice Diaz Study Coordinator
Karen Aleman Study Coordinator
Yale University, New Haven, Connecticut (SG, B, AV, MK) Christopher Van Dyck Principal Investigator
Ming‐Kai Chen Imaging Principal Investigator
Nina Diepenbrock Study Coordinator
Adam Mecca, MD, PhD Sub‐Investigator
Susan Good, APRN Study Nurse
University of California, San Diego (SG, B, AV, MK) Doug Galasko Principal Investigator
Carl Hoh Imaging Principal Investigator
Dan Szpak Study Coordinator
Shawnees Peacock Back up Coordinator
University of Washington (SG, B, AV, MK) Suman Jayadev Principal Investigator
David Lewis Imaging Principal Investigator
Yeung Tuttero Study Coordinator
Advocate Lutheran General Hospital, Park Ridge, Illinois Darren Gitelman Principal Investigator
Victoria Begoun Study Coordinator
Evelyn Torres Back up Coordinator
AUSC Keck School of Medicine, Los Angeles, California Sonia Pawluczyk Principal Investigator
Columbia University, New York City (SG, B, AV, MK) Lawrence Honig Principal Investigator
Chaitanya Divgi Imaging Principal Investigator
Ruth B. Tejeda Rater
Solciris A. Dominguez Rater
Katrina Cuasay Rater
Evelyn Dominquez‐Rivera Study Coordinator
Kerwin Research Center, Dallas, Texas Diana Kerwin Principal Investigator
Micah Eimberbrink, PhD Head of Research Operations Legend for site participation: SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run‐in
Version 25, January 2020
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
DIAN EXR Referring Clinicians and Researchers
Neelum T. Aggarwal, MD, Rush University Medical Center, Chicago IL Tom Ala, Center for Alzheimer’s Disease and Related Disorders, Southern Illinois University School of Medicine Thomas Bird, University of Washington Sandra E. Black, Sunnybrook Health Sciences Centre, University of Toronto William J. Burke, MD, Banner Alzheimer’s Institute Cynthia M. Carlsson, MD, MS, University of Wisconsin School of Medicine and Public Health Andrew Frank M.D. B.Sc.H. F.R.C.P.(C), Bruyere Continuing Care, Ottawa, Ontario, Canada James E. Galvin, MD, MPH, Charles E. Schmidt College of Medicine, Florida Atlantic University Alvin C Holm, MD, Bethesda Hospital, St. Paul, MN John S.K. Kauwe, Brigham Young University David Knopman MD, Mayo Clinic, Rochester MN Sarah Kremen, MD, University of California, Los Angeles Alan J. Lerner, University Hospitals Cleveland Medical Center Barry S. Oken, MD, PhD, Oregon Health & Science University Hamid R. Okhravi, Eastern Virginia Medical School Ronald C. Petersen, Mayo Clinic Aimee L. Pierce, MD, University of California Irvine Marsha J. Polk, MED, University of Texas Health Science Center at San Antonio John M. Ringman, MD, MS, University Southern California Sanjeev N. Vaishnavi, MD, PhD, University of Pennsylvania Sandra Weintraub, Northwestern University Feinberg School of Medicine
DIAN‐TU Collaborators and Advisers
John Morris, MD, Senior Advisor David Holtzman, MD, Senior Advisor Thomas Bird, MD, University of Washington Dennis Dickinson, MD, Mayo Clinic, Jacksonville, FL Peter St. George Hyslop, MD, FRS, FRSC, FRCPC, University of Toronto M. Marsel Mesulam, MD, Cognitive Neurology and Alzheimer’s Disease Center, Northwestern University Cornelia Kamp, MBA, University of Rochester ADCS Ron Thomas, PhD Paul Aisen, MD